{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:31:37Z","timestamp":1786645897781,"version":"build-2736575974"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Background\/Aims:<\/jats:title>\n MicroRNA-429 (miR-429), a member of the miR-200 family, has been implicated in epithelial\u2013mesenchymal transition and tumor progression, yet its clinicopathological significance in breast cancer remains unclear. This study aimed to evaluate serum miR-429 expression in treatment-na\u00efve breast cancer patients and correlate its levels with detailed histopathological variables, molecular subtype, treatment response, and outcome.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n In this prospective study, serum samples from 49 invasive ductal carcinoma (IDC- no special type [NST]) patients and 49 age-matched healthy controls were analyzed by quantitative real-time polymerase chain reaction. Clinicopathological data (tumor grade, receptor status, lymphovascular invasion [LVI], nodal status, mitosis, tumor-infiltrating lymphocytes, necrosis, and subtype) and treatment response (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) were recorded. Resection specimens were evaluated for residual cancer burden (RCB).<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Mean serum miR-429 levels were significantly lower in cases than controls (0.92 \u00b1 0.53 vs. 1.24 \u00b1 0.55;\n t<\/jats:italic>\n = 2.892,\n P<\/jats:italic>\n = 0.005). Receiver operating characteristic analysis showed an area under the curve of 0.649 (95% confidence interval: 0.540\u20130.758;\n P<\/jats:italic>\n = 0.011) with 67.3% sensitivity and specificity at a cut-off of <1.005. Higher miR-429 expression was significantly associated with LVI (37.5% vs. 0%,\n P<\/jats:italic>\n = 0.021). Trends toward higher mitotic activity (\u22656 mitoses\/10 hpf: 62.5% vs. 25.0%,\n P<\/jats:italic>\n = 0.094) and greater nodal involvement (50.0% vs. 20.0%,\n P<\/jats:italic>\n = 0.096) were noted in the high-expression group. No significant associations were observed with grade (\n P<\/jats:italic>\n = 0.190), receptor status (estrogen receptor\n P<\/jats:italic>\n = 0.354; progesterone receptor\n P<\/jats:italic>\n = 0.614; HER2\n P<\/jats:italic>\n = 0.579), molecular subtype (\n P<\/jats:italic>\n = 0.852), RCB (\n P<\/jats:italic>\n = 0.418), or RECIST response (\n P<\/jats:italic>\n = 0.627). At follow-up, 42 patients (85.7%) were doing well, 5 (10.2%) had died, and outcomes were not significantly related to miR-429 (\n P<\/jats:italic>\n = 0.351).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Serum miR-429 is downregulated in breast cancer and correlates significantly with LVI, suggesting a role in invasive biology. While diagnostic utility is modest, its integration into multi-microRNA panels may enhance predictive accuracy. Larger, multi-institutional, subtype-stratified studies are needed for validation.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/aam.aam_560_26","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:01:58Z","timestamp":1786644118000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological and Prognostic Implications of Circulating MicroRNA-429 in Breast Cancer Patients"],"prefix":"10.4103","author":[{"given":"Shivangini","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taniya","family":"Suryavanshi","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulranjan","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Solanki","sequence":"additional","affiliation":[{"name":"Department of Obs and Gynae, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,14]]},"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_560_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:01:59Z","timestamp":1786644119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_560_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":0,"URL":"https:\/\/doi.org\/10.4103\/aam.aam_560_26","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2026-05-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}